Rashtriya Newsflash

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Essential Thrombocythemia (ET) Market Insights, Epidemiology, and Market Forecast 2034.” This comprehensive report provides an in-depth understanding of ET, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Essential Thrombocythemia (ET) Market

• The market size for Essential Thrombocythemia in the 7MM is expected to increase significantly during the forecast period 2020–2034.

• The United States accounted for the highest ET market size among the 7MM in 2024 compared to EU4 countries, the United Kingdom, and Japan.

• According to a study conducted by Thompson et al., the estimated prevalence of ET was around 18 cases per 100,000 population annually.

• In France, approximately 1–2.5 new cases per 100,000 inhabitants are reported annually, while the prevalence is nearly 1 case per 3,330 individuals.

• According to Bloodwise, nearly 60% of ET patients harbor the JAK2 mutation, around 30% have CALR mutations, and approximately 5% possess MPL mutations.

• Leading ET companies such as Merck, PharmaEssentia, Novartis, and pharma& are developing innovative therapies to improve treatment outcomes and reduce thrombotic complications associated with ET.

• Promising ET pipeline therapies include BESREMi (ropeginterferon alfa-2b), Bomedemstat (MK-3543/IMG-7289), Pelabresib, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/essential-thrombocythemia-et-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Essential Thrombocythemia Market

Increasing Disease Prevalence and Improved Diagnosis:Rising awareness regarding myeloproliferative neoplasms, along with increasing adoption of genetic mutation testing for JAK2, CALR, and MPL mutations, is supporting earlier diagnosis and improved disease management.

Growing Focus on Prevention of Thrombotic Complications:The primary treatment objective in ET remains the prevention of thrombotic and hemorrhagic events, which are major causes of morbidity and mortality among ET patients.

Emergence of Novel Targeted Therapies:The growing development of targeted therapies including LSD1 inhibitors, interferons, and BET inhibitors is expected to improve long-term disease control and therapeutic outcomes in ET patients.

Essential Thrombocythemia Competitive Landscape

• Several ET therapies in development include Bomedemstat (Merck), Ropeginterferon alfa-2b (PharmaEssentia), and Pelabresib (Novartis).

• These therapies target diverse mechanisms such as LSD1 inhibition, interferon stimulation, and BET protein inhibition aimed at improving hematologic response, reducing thrombosis risk, and enhancing long-term disease management in ET patients.

Discover more about therapies set to grab major Essential Thrombocythemia market share @ Essential Thrombocythemia Treatment Landscape

Recent Developments in the Essential Thrombocythemia Market

• In November 2025, Merck presented Phase III extension study data evaluating the safety of Bomedemstat in ET patients at the American Society of Hematology (ASH) Annual Meeting and Exposition.

• In July 2025, pharma& announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for PEGASYS as a monotherapy treatment for adults with ET and polycythemia vera.

• In November 2025, PharmaEssentia announced positive results from the pivotal Phase III SURPASS-ET clinical trial evaluating ropeginterferon alfa-2b.

• In November 2025, PharmaEssentia also announced expectations for US FDA regulatory approval of ropeginterferon alfa-2b in 2026 following regulatory submission planned by the end of 2025.

What is Essential Thrombocythemia (ET)?

• Essential Thrombocythemia is a chronic myeloproliferative neoplasm characterized by excessive production of platelets in the bone marrow. The disease is associated with an increased risk of thrombosis, hemorrhage, and transformation into myelofibrosis or acute leukemia.

• ET is commonly associated with mutations in JAK2, CALR, and MPL genes. Diagnosis typically involves bone marrow biopsy, genetic testing, and evaluation of clinical risk factors.

• Current treatment strategies focus on reducing platelet counts and preventing vascular complications using therapies such as aspirin, hydroxyurea, interferons, and anagrelide.

Essential Thrombocythemia Epidemiology Segmentation

The Essential Thrombocythemia epidemiology section provides insights into the historical and current ET patient pool and forecasted trends for the leading markets. The ET market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of ET

• Symptom-specific Cases of ET

• Gender-specific Cases of ET

• Mutation-specific Cases of ET

• Risk-specific Cases of ET

• Age-specific Cases of ET

• Total Treated Cases of ET

Scope of the Essential Thrombocythemia Market Report

• Therapeutic Assessment: ET current marketed and emerging therapies

• ET Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: Merck, PharmaEssentia, Novartis, pharma&, and others

• Key Therapies: PEGASYS, BESREMi, Bomedemstat, Pelabresib, Hydroxyurea, Aspirin, Anagrelide, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, ET Market Access and Reimbursement

To know more about Essential Thrombocythemia companies working in the treatment market, visit @ Essential Thrombocythemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Essential Thrombocythemia Market Report Introduction

2. Executive Summary for ET

3. SWOT Analysis of ET

4. ET Patient Share (%) Overview at a Glance

5. ET Market Overview at a Glance

6. ET Background and Overview

7. ET Epidemiology and Patient Population

8. Country-Specific Patient Population of ET

9. ET Current Treatment and Medical Practices

10. ET Unmet Needs

11. ET Emerging Therapies

12. ET Market Outlook

13. Country-Wise ET Market Analysis (2020–2034)

14. ET Market Access and Reimbursement of Therapies

15. ET Market Drivers

16. ET Market Barriers

17. ET Appendix

18. ET Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services